Testing a new seizure medication added to current treatments

Plain-English translation of NCT05667142 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new medication called as an add-on treatment for people with generalized epilepsy who experience primary generalized tonic-clonic seizures. Researchers want to see if this medication, taken once daily, can help reduce seizure frequency when combined with anti-seizure medications you may already be taking. About 160 people will participate across multiple locations.

Many people with generalized epilepsy don't achieve full seizure control even when taking one or more anti-seizure medications. This trial exists to find out whether this new medication could help those patients get better control of their seizures when added to their current treatment plan.

Do you qualify?

You likely qualify if…

you are at least 12 years old and have a BMI of 40 or less
you have been diagnosed with generalized epilepsy and experience primary generalized tonic-clonic seizures for at least one year
you have already tried at least two different anti-seizure medications at full doses without achieving complete seizure control
you are currently taking one to three anti-seizure medications at a stable dose
you are able to keep an accurate daily diary of your seizures
you are willing to give written informed consent (or your parent or guardian consents if you are under 18)

You likely don't qualify if…

you have had status epilepticus (prolonged or back-to-back seizures) in the past 12 months
you have had brain surgery or radiosurgery for seizures in the past year or two
you have a serious mental health condition like schizophrenia, bipolar disorder, or uncontrolled depression
you have a history of non-epileptic psychogenic seizures in the past 10 years
you have focal-onset seizures or Lennox-Gastaut syndrome as part of your diagnosis

What participation looks like

You would first spend about 9.5 weeks tracking your baseline seizure patterns. Then you would be randomly assigned to receive either the new medication or a placebo, taking one pill daily with an evening meal for 12 weeks. You'll continue taking your current seizure medications throughout the study. After the 12-week treatment phase, you can choose to enter an extended open-label study to continue the medication, or you'll be monitored for 8 more weeks as the medication leaves your system.

AI-generated summary from trial data · Jul 10, 2026 · Not medical advice

Trial locations(138 sites)

United States

University of Alabama - Strada Patient Care Center, Neurology, Mobile, Alabama

Xenoscience, Phoenix, Arizona

University of Arizona - Health Science Center, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Brain Science Research Institute, Los Angeles, California